CB-307 is under clinical development by Crescendo Biologics and currently in Phase I for Metastatic Castration-Resistant Prostate Cancer (mCRPC). According to GlobalData, Phase I drugs for Metastatic Castration-Resistant Prostate Cancer (mCRPC) have an 88% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how CB-307’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

CB-307 overview

CB-307 is under development for the treatment of PSMA-positive solid tumors and metastatic castration resistant prostate cancer with only bone metastasis. It consists of bi-specific VH domains which targets prostate-specific membrane antigen (PSMA) and CD137. The drug candidate is developed based on Humabody technology. It is administered through intravenous route.

Crescendo Biologics overview

Crescendo Biologics (Crescendo) is a clinical stage immuno-oncolgy company that manufactures antibody therapeutics based on a transgenic mouse platform. The company offers pipeline product include PSMA x CD137 x HSA (CB307), MSLN x CD137 x HSA (CB693), 5T4x CD137 x HSA, ROR1x CD137 x HSA, LAG-3 PD-1 x HSA (CB213). MSLN x CD137 x HSA (CB693), 5T4x CD137 x HSA, ROR1x CD137 x HSA are developed for the treatment of for the treatment of cancers. CD137 x PSMA Humabody, is for the selective activation of tumor specific T cells withinn the tumor microenvironment. CD137 x PSMA Humabody is developed for the treatment of different cancer types. It offers services such as clinical trials. It markets its products under the brand name Humabody. It has business partnership with Soffinova partners, Andera Partners, IP Group, BioNTech, Takeda and Quan Capital. Crescendo is headquartered in Cambridge, Cambridgeshire, the UK.

For a complete picture of CB-307’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.